Dyax Corp., a biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for conditions identified as plasma kallikrein (bradykinin) mediated angioedema, including hereditary angioedema (HAE), ACE inhibitor-induced angioedema (ACEI-AE), and angioedema. The company develops KALBITOR (ecallantide) by using its phage display technology for the treatment of acute attacks of HAE. It markets KALBITOR through exclusive wholesale and co-exclusive specialty pharmacy arrangements in the United States. The company is also involved in the clinical development of ecallantide for use in the treatment of ACEI-AE; and development of a human monoclonal antibody inhibitor of plasma kallikrein, which is a candidate to prophylactically treat plasma kallikrein (bradykinin) mediated angioedemas. In addition, the company, through licensing and funded research program (LFRP), has 18 product candidates in clinical development. Dyax Corp, under LFRP program, grants its licensees the rights to use its phage display libraries in connection with their internal therapeutic development programs under the library license program; performs funded research for various collaborators using its phase display technology to identify, characterize, and optimize antibodies under the funded research program; and grants other biopharmaceutical and pharmaceutical companies non-exclusive licenses to use its core phage display patents to discover and develop biologic compounds for use in specified fields under the patent license program. It has a strategic collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize ecallantide for the treatment of HAE and other therapeutic indications in Europe, North Africa, the Middle East, and Russia. The company was founded in 1989 and is headquartered in Burlington, Massachusetts.